THALIDOMIDE TREATMENT REDUCES COLON INJURY INDUCED BY EXPERIMENTAL COLITIS

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Shock

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.shk.0000163385.12490.9dPMID 15897810
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease

  2002cited by this paper
• The present status and the recent development of the treatment for inflammatory bowel diseases: desirable effect of extracorporeal immunomodulation.

  2002cited by this paper
• VEGF, basic-FGF, and TGF-β in Crohn’s disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation

  2001cited by this paper
• Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)

  2001cited by this paper
• Thalidomide impairment of trinitrobenzene sulphonic acid‐induced colitis in the rat–role of endothelial cell‐leukocyte interaction

  2001cited by this paper
• Role of vascular endothelial growth factor in regulation of physiological angiogenesis.

  2001cited by this paper
• Mean platelet volume: a useful marker of inflammatory bowel disease activity

  2001cited by this paper
• Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat

  2001cited by this paper
• VEGF, basic-FGF, and TGF-β in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation

  2001cited by this paper
• T Regulatory Cells 1 Inhibit a Th2-Specific Response In Vivo1

  2000cited by this paper
• Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity.

  2000cited by this paper
• Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1).

  2000cited by this paper
• Tumor necrosis factor: biology and therapeutic inhibitors.

  2000cited by this paper
• Thrombocytes Are the Major Source for Soluble Vascular Endothelial Growth Factor in Peripheral Blood

  2000cited by this paper
• Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper

  2000cited by this paper
• Therapeutic angiogenesis for heart failure

  1999cited by this paper
• An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

  1999influential reference
• Th1/Th2 cells.

  1999cited by this paper
• Blockade of Poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis.

  1999cited by this paper
• Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis

  1999cited by this paper
• Elevated Serum Vascular Endothelial Growth Factor in Children and Young Adults with Crohn's Disease

  1999cited by this paper
• Crohn's disease is associated with novel polymorphisms in the 5'-flanking region of the tumor necrosis factor gene.

  1999cited by this paper
• Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase

  1999cited by this paper
• Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

  1999cited by this paper
• Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

  1999cited by this paper
• Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion.

  1998cited by this paper
• Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils

  1998cited by this paper
• Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome

  1998cited by this paper
• In vitro release of vascular endothelial growth factor during platelet aggregation.

  1998cited by this paper
• The effect of thalidomide and 2 analogs on collagen induced arthritis.

  1998cited by this paper
• Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease.

  1998cited by this paper
• Inflammatory bowel disease: etiology and pathogenesis.

  1998cited by this paper
• Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells.

  1998cited by this paper
• CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.

  1998cited by this paper
• Tumor Necrosis Factor-α Regulates Expression of Vascular Endothelial Growth Factor Receptor-2 and of Its Co-receptor Neuropilin-1 in Human Vascular Endothelial Cells*

  1998cited by this paper
• What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo?

  1997cited by this paper
• Platelet: transporter of vascular endothelial growth factor.

  1997cited by this paper
• Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells.

  1997cited by this paper
• Inhibition of IL-12 production by thalidomide.

  1997cited by this paper
• Effects of Cyclosporin A on Paracellular and Transcellular Transport of Horseradish Peroxidase in Perfused Rat Livers

  1997cited by this paper
• Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease.

  1997cited by this paper
• Inhibition of poly (ADP-ribose) Synthetase Attenuates Neutrophil Recruitment and Exerts Antiinflammatory Effects

  1997cited by this paper
• Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.

  1997cited by this paper
• A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.

  1997cited by this paper
• Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases.

  1997cited by this paper
• Thalidomide in Crohn's disease.

  1997cited by this paper
• A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

  1997cited by this paper
• Thalidomide in Crohn's disease.

  1997cited by this paper
• In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.

  1997cited by this paper
• Lymphocyte Homing and Homeostasis

  1996cited by this paper
• Leukocyte adhesion and hepatic microvascular responses to intestinal ischemia/reperfusion in rats.

  1996cited by this paper
• Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease.

  1996cited by this paper
• Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.

  1996cited by this paper
• Time course of ICAM-1 expression and leukocyte subset infiltration in rat forebrain ischemia.

  1995cited by this paper
• Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.

  1995cited by this paper
• P-selectin and vascular cell adhesion molecule 1 mediate rolling and arrest, respectively, of CD4+ T lymphocytes on tumor necrosis factor alpha-activated vascular endothelium under flow

  1995cited by this paper
• Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

  1995cited by this paper
• Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis.

  1995cited by this paper
• Intercellular adhesion molecule 1 (ICAM‐1) expression and its role in neutrophil‐induced ischemia‐reperfusion injury in rat liver

  1995cited by this paper
• Oxidants and free radicals in inflammatory bowel disease.

  1994cited by this paper
• Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.

  1994cited by this paper
• Role of P-selectin in microvascular leukocyte-endothelial interaction in splanchnic ischemia-reperfusion.

  1994cited by this paper
• Chronic Cutaneous Lupus Erythematosus Treated With Thalidomide

  1993cited by this paper
• Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats

  1993cited by this paper
• Peroxynitrite-induced rat colitis--a new model of colonic inflammation.

  1993cited by this paper
• Chronic cutaneous lupus erythematosus treated with thalidomide.

  1993cited by this paper
• Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock.

  1993cited by this paper
• Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis.

  1992cited by this paper
• Thalidomide for the treatment of chronic graft-versus-host disease.

  1992cited by this paper
• Peroxynitrite formation from macrophage-derived nitric oxide.

  1992cited by this paper
• Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140).

  1992cited by this paper
• Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface.

  1992cited by this paper
• Thalidomide treatment for chronic graft‐versus‐host disease

  1991cited by this paper
• Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

  1991cited by this paper
• Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide.

  1990cited by this paper
• Oxygen-derived free radical generating capacity of polymorphonuclear cells in patients with ulcerative colitis.

  1989cited by this paper
• Hapten-induced model of chronic inflammation and ulceration in the rat colon.

  1989cited by this paper
• Treatment of refractory rheumatoid arthritis--the thalidomide experience.

  1989cited by this paper
• Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium.

  1985cited by this paper
• The metabolic fate of supidimide in the rat.

  1982cited by this paper
• THALIDOMIDE AND CONGENITAL ABNORMALITIES

  1962cited by this paper

• Gastrointestinal inflammation plays a critical role in chemotherapy-induced nausea and vomiting.

  2022cites this paper
• Effect of hesperetin on inflammatory and oxidative status in trinitrobenzene sulfonic acid-induced experimental colitis model.

  2018cites this paper
• Study of the Interactions of Bovine Serum Albumin with the New Anti-Inflammatory Agent 4-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-N′-[(4-ethoxy-phenyl)methylidene]benzohydrazide Using a Multi-Spectroscopic Approach and Molecular Docking

  2017cites this paper
• Determination of (4-(1,3-dioxo-1,3-dihydro-2H-isoindol- 2-yl)-N'-[(4-ethoxyphenyl) methylidene] benzohydrazide, a novel anti-inflammatory agent, in biological fluids by UPLC-MS/MS: Assay development, validation and in vitro metabolic stability study.

  2017cites this paper
• Design and Synthesis of N-Arylphthalimides as Inhibitors of Glucocorticoid-Induced TNF Receptor-Related Protein, Proinflammatory Mediators, and Cytokines in Carrageenan-Induced Lung Inflammation.

  2015cites this paper
• Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.

  2015cites this paper
• The effect of thalidomide on ethanol-induced gastric mucosal damage in mice: involvement of inflammatory cytokines and nitric oxide.

  2015cites this paper
• Protective effect of royal jelly in 2,4,6 trinitrobenzene sulfonic acid-induced colitis in rats

  2015cites this paper
• Treatment of inflammatory bowel disease (IBD)

  2011cites this paper
• Treatment of Suqingwan watered pill reduces colon injury induced by experimental colitis.

  2011cites this paper
• THALIDOMIDE SUPPRESSES SCLEROSING ENCAPSULATING PERITONITIS IN A RAT EXPERIMENTAL MODEL

  2009cites this paper
• Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production.

  2007cites this paper
• From model to mechanism: lessons of mice and men in the discovery of protein biologicals for the treatment of inflammatory bowel disease

  2006cites this paper
• Tissue‐specific expression of estrogen receptors and their role in the regulation of neutrophil infiltration in various organs following trauma‐hemorrhage

  2006cites this paper
• THALIDOMIDE TREATMENT REDUCES THE ALTERATION OF PARACELLULAR BARRIER FUNCTION IN MICE ILEUM DURING EXPERIMENTAL COLITIS

  2006cites this paper
• Role of angiogenesis in inflammatory bowel disease

  2006cites this paper
• Mouse models of inflammatory bowel disease.

  2006cites this paper
• Preparation and In Vitro Analysis of Microcapsule Thalidomide Formulation for Targeted Suppression of TNF-α

  2006cites this paper
• Iranian Journal of Basic Medical Sciences Protective Effect of Royal Jelly in 2,4,6 Trinitrobenzene Sulfonic Acid-induced Colitis in Rats

  year unknowncites this paper